Heterogeneity of cancer phenotypes is the root cause behind inefficient tumour eradication and drug resistance after treatment. To overcome these challenges, in this project we explore a radically new approach: kill cancer cells based on their genotype, i.e. target patient specific DNA mutations rather than phenotypic characteristics. Students will be involved in genetic engineering, designing and building novel synthetic constructs based on the latest generation of RNA sensors, and test candidate systems for specificity and efficiency on a range of cancer cell lines, including leukaemia and breast cancer.
This project is ideal for those with a keen interest in the vanguard fields of synthetic biology, protein engineering, and molecular biology. Not only will students have the opportunity to develop a new class of anti-cancer therapeutics, but will also gain hands-on experience in cutting-edge CRISPR techniques, contribute to high-impact research, and work in a dynamic and supportive team.
